AFTX-201: A next-generation, one-time genetic medicine for BAG3 DCM
Date: June 10, 2026
Time: 6:00pm EDT
Please join us for an educational webinar about AFTX-201, a next generation, investigational gene therapy that has been designed as a one-time treatment for patients with dilated cardiomyopathy due to mutations in the BAG3 gene. We’ll talk about the journey of Affinia Therapeutics and AFTX-201 to the first-in-human clinical trial.
We’ll also share an overview of the UPBEAT© trial, a multi-center, open-label, Phase 1b/Phase 2, dose-exploration, and dose-expansion trial of AFTX-201 for patients with dilated cardiomyopathy due to mutations in BAG3. The goal of the study is to help researchers better understand the safety and potential for efficacy of AFTX-201. We’ll explain what taking part may look like, who may be eligible, and how to learn more.
There will also be a Question-and-Answer section at the end of the webinar to answer any questions that you might have.
If you, a family member, or someone that you know has dilated cardiomyopathy due to mutations in the BAG3 gene you should attend. We also encourage all Health Care Providers that might have patients with mutations in the BAG3 gene to join this webinar.
Presenters:
Hideo Makimura, M.D., Ph.D.
Chief Medical Officer
Affinia Therapeutics
Arvind Bhimaraj, M.D.
Advanced Heart Failure Cardiologist and Physician Scientist
Principal Investigator, UPBEAT© trial
Houston Methodist Hospital
Targeting the Genetic Root Cause: Atrium Therapeutics’ RNA Approach to Rare Cardiomyopathies
Date: August 19, 2026
Time: 6:00pm EDT
Join Atrium Therapeutics for an introduction to the company and its mission to pioneer targeted RNA delivery directly to the heart, transforming care for people living with rare, life-threatening genetic cardiomyopathies. Hear how Atrium’s lead programs — ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy — are designed to address the underlying genetic drivers of these conditions for the first time.
Dr. Husam Younis is Chief Scientific Officer at Atrium Therapeutics, with more than 20 years of experience in drug discovery and development, including in rare disease. He has held senior leadership roles in research and development science at Avidity Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals and Pfizer. His experience spans multiple drug modalities and therapeutic areas and he has led research and development teams to advance multiple programs from preclinical research to first-in-human studies and to BLA submission. Dr. Younis completed his graduate training in pharmacology and toxicology and pharmacy practice at the College of Pharmacy at the University of Arizona.
Sharon Paige, MD, PhD is a physician-scientist and pediatric cardiologist with deep expertise in cardiac genetics, cardiomyopathy, congenital heart disease, and stem cell biology. She currently is the Clinical Development lead for the PRKAG2 program at Atrium Therapeutics, where she helps advance innovative therapeutic approaches for patients with inherited cardiovascular disease. Dr. Paige has dedicated her career to bridging translational research and patient-centered care, with a strong commitment to improving outcomes for patients of all ages affected by rare and genetic heart conditions. She is passionate about collaborating with patient advocacy organizations to accelerate research, education, and access to emerging therapies.